Cooley LLP announced today that it advised Alder Biopharmaceuticals, Inc. on its $80 million initial public offering. Alder is a Washington-based clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder is currently developing two lead product candidates: ALD403, an investigational monoclonal antibody for migraine, and Clazakizumab, an investigational monoclonal antibody for rheumatoid arthritis and other autoimmune indications, in collaboration with Bristol-Myers Squibb. The company now trades on the NASDAQ Global Stock Market under the symbol “ALDR.”
The Cooley corporate and securities team advising Alder was led by partners Sonya Erickson and John McKenna and included associates Julia Conway, Alan Hambelton, Michael Pirog and Yuri Weigel. Critical support for the offering was provided by partners Renee Deming and Amy Wood and special counsel Jeannie Leahy (compensation & benefits); partners Natasha Leskovsek and Marya Postner (regulatory & licensing); and partners Mark Windfeld-Hansen and Susan Philpot (tax).
